Adaptimmune Therapeutics Plc (ADAPY)
0.0485
0.00 (0.00%)
USD |
OTCM |
Dec 11, 16:00
Adaptimmune Therapeutics Cash from Investing (Quarterly): 18.84M for June 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -0.0656M |
| Autolus Therapeutics Plc | 35.49M |
| Mereo BioPharma Group Plc | 0.3027M |
| Bicycle Therapeutics Plc | -0.6709M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -35.40M |
| Cash from Financing (Quarterly) | 1.548M |
| Free Cash Flow | -193.83M |
| Free Cash Flow Per Share (Quarterly) | -0.1343 |
| Free Cash Flow to Equity (Quarterly) | -35.45M |
| Free Cash Flow to Firm (Quarterly) | -34.57M |
| Free Cash Flow Yield | -1.55K% |